dr. meisel on optimizing genomic assays in early-stage hr-positive, her2-negative breast cancer
Published 5 years ago • 331 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:03:44
new & supporting data for optimizing therapy in her2 breast cancer | dr. meisel & dr. soliman
-
1:38
genomic assays for chemotherapy decisions in er-positive/her2-negative breast cancer
-
1:04
dr. meisel on emerging treatment strategies in tnbc
-
1:30
utilizing genomic assays for decision making in early stage breast cancer
-
0:52
dr. graff on genomic risk prediction in hr /her2- breast cancer
-
7:11
genomic testing for risk of late recurrence/asco guidelines
-
1:30
dr. brufsky on genomic assays for breast cancer
-
1:40
dr. simon on genomic assays for patients with breast cancer
-
2:34
genomic assays impact treatment decisions in patients with er breast cancer
-
1:49
dr. brufsky on multiparametric genomic assays in breast cancer
-
28:11
2021 mdons | the nurses role in early stage breast cancer | a focus on genomic assays
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
18:45
agendia: the new era of genomic testing in early stage breast cancer.
-
8:26
adjuvant strategies in early-stage her2 breast cancer
-
1:59
dr. melisko reflects on findings from the mindact trial in breast cancer
-
1:18
dr. graff on extended adjuvant therapy in early-stage hr breast cancer
-
1:07
jane meisel, md | advice on metastatic breast cancer at 2019 asco direct highlights st. louis
-
14:37
genomic testing in breast cancer: what you must know
-
14:21
genomic testing during breast cancer: should you have testing?